Transforming Growth Factor-Beta and the Kidney: What We Know and What We Can Do?

Author(s): Hai-Chun Yang, Yiqin Zuo, Agnes B. Fogo

Journal Name: Current Enzyme Inhibition

Volume 6 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-β interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.

Keywords: TGF-β, kidney, fibrosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [87 - 96]
Pages: 10
DOI: 10.2174/157340810791233042
Price: $65

Article Metrics

PDF: 8